COMPANY

ROHTO Pharmaceutical Co., Ltd.

Articles that reconnect the numbers in this company’s primary sources into a clearer picture of the business.

ROHTO Pharmaceutical Co., Ltd.Year ended March 2026

Rights, ownership and new brands: how Rohto assembled its portfolio.

¥343.7bnFY2026 consolidated revenue (rounded)
62%Skincare share of FY2025 product and service sales
18%Eye-care share of FY2025 product and service sales
What emerges

Brand rights, business acquisitions and product launches coexist in Rohto’s portfolio. Skincare contributed 62% of FY2025 sales and eye care 18%. Those proportions do not prove that one acquisition or technology created the mix; they show how much lies beyond the familiar eye-drop identity.

See the company through the numbers →